Table 3.
Clinical Outcome Measures in Full, Incident, and Established MTX User Cohorts - Mean (S.D.)
| Course | Full Cohort | Incident User Cohort | Established User Cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MPR<80% (n=71) | MPR ≥80% (n=384) | p-value | MPR<80% (n=17) | MPR ≥80% (n=68) | p-value | MPR<80% (n=54) | MPR ≥80% (n=316) | p-value | |
| Primary Outcome Measure | |||||||||
| DAS28 | 3.9 (1.5) | 3.6 (1.2) | 0.02 | 4.2 (1.4) | 3.6 (1.1) | 0.10 | 3.8 (1.5) | 3.5 (1.2) | 0.09 |
| Secondary Outcome Measures | |||||||||
| Erythrocyte sedimentation rate mm/hr | 29 (24) | 24 (18) | 0.05 | 35.2 (26) | 25 (17) | 0.05* | 27.4 (23.0) | 24.2 (18.4) | 0.26 |
| C-reactive Protein mg/dl | 1.6 (1.5) | 1.2 (1.3) | 0.03 | 1.8 (1.6) | 1.4 (1.9) | 0.51 | 1.6 (1.5) | 1.2 (1.2) | 0.03 |
| Tender Joints (0–28) | 5.4 (6.2) | 3.6 (4.5) | <0.01 | 4.9 (4.7) | 3.6 (4.4) | 0.28 | 5.6 (6.71) | 3.7 (4.6) | 0.02 |
| Swollen Joints (0–28) | 4.3 (4.8) | 3.2 (3.3) | 0.02 | 4.6 (4.6) | 3.2 (3.5) | 0.19 | 4.3 (4.9) | 3.2 (3.2) | 0.03 |
| Health Assessment Questionnaire (0–3.0) | 0.9 (0.56) | 0.9 (0.52) | 0.93 | 1.0 (0.45) | 0.9 (0.54) | 0.66 | 0.9 (0.6) | 0.9 (0.9) | 0.75 |
| Visual Analogue Scale | 38 (24) | 39 (20) | 0.63 | 37 (21) | 32 (19) | 0.27 | 35 (28) | 39 (20) | 0.22 |
| Patient Global | 37 (24) | 39 (20) | 0.30 | 41 (23) | 41 (21) | 0.975 | 34 (24) | 33 (17) | 0.40 |
| Pain (0–10) | 4.4 (2.7) | 4.2 (2.2) | 0.71 | 3.8 (2.9) | 4.4 (2.1) | 0.33 | 4.5 (2.6) | 4.21 (2.2) | 0.34 |
*
= P <0.05 and marked in bold